Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV- 574) Antibody at the 2024 ECCO Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A 1
Anti-TL1A was shown to be safe and well-tolerated, with a low incidence of antidrug.
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV- 574) Antibody at the 2024 ECCO Annual Meeting pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
– A total of 17 accepted abstracts, including nine oral presentations and eight posters, reinforce AbbVie s commitment to produce a portfolio of products that aim to improve the lives of patients.
PARIS, FRANCE / ACCESSWIRE / February 13, 2024 / Abivax SA (Euronext Paris:ABVX))(NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients.